Flexural eczema
Methodology & AI Transparency ⓘ
Flexural eczema Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Flexural eczema (ICD-10-CM L20.82), Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols prioritize or targeted biologics [Flexural eczema L20.82] paired with baseline and interval Affected Body Surface in Flexural eczema (L20.82: Area (BSA /) assessment.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM L20.82 for Flexural eczema clinical workups.
- 3 Typical cash cost range: Workup highlights for Flexural eczema (L20.82): or targeted biologics [Flexural eczema L20.82].
- 4 Top reported side effects / signs: Objective lab/clinical target for Flexural eczema: Affected Body Surface in Flexural eczema (L20.82: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L20.82)) and Fasting Lipids & in Flexural eczema (L20.82: ALT (if systemic).
Ask our AI Specialists anything about Flexural eczema
What Is Flexural eczema?
For patients presenting with Flexural eczema (ICD-10-CM L20.82), Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols prioritize or targeted biologics [Flexural eczema L20.82] paired with baseline and interval Affected Body Surface in Flexural eczema (L20.82: Area (BSA /) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in skin & dermatology, Flexural eczema (L20.82) involves epidermal barrier filaggrin/ceramide in Flexural eczema (L20.82: disruption). progression correlates with shifts in Affected Body Surface in Flexural eczema (L20.82: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L20.82)).
Common Symptoms & Clinical Signs
- • Presentation of Flexural eczema (L20.82): post-inflammatory hyperpigmentation, facial in Flexural eczema (L20.82: flushing, or pitted)
- • Secondary Flexural eczema clinical sign: recurrent flares triggered in Flexural eczema (L20.82: by UV exposure,)
- • Symptom flares in Flexural eczema correlating with Affected Body Surface in Flexural eczema (L20.82: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L20.82)
- • Functional skin & dermatology impact requiring or targeted biologics [Flexural eczema L20.82] evaluation (L20.82)
Flexural eczema Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L20.82 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Flexural eczema (L20.82: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L20.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Flexural eczema (L20.82: ALT (if systemic) | Within baseline reference limits (L20.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Flexural eczema (L20.82: & hs-CRP) | 25(OH)D 40–65 ng/mL (L20.82) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Flexural eczema
Treatment selection for Flexural eczema depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Flexural eczema)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of a New Botulinum Toxin (HU-014) Versus Existing: What a 267-Participant Study Found HU-014 was noninferior to existing onabotulinumtoxin A in the treatment of glabellar lines at a 1:1 dose ratio, and both products were well tolerated. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2021-03-01 • Phase III Randomized Trial | N = 267 | 93/100 | PMID 33481449 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe Upadacitinib 15 mg and 30 mg single-drug treatment provided rapid and sustained improvement in atopic hand eczema compared with placebo through Week 16 in patients with moderate-to-severe AD. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37184290 ↗ |
| Can This Approach Help? Inside the Latest Research on Aesthetic Improvements Over Time: Long-Term Efficacy and Additional Outcomes of Additional endpoints, including pGAIS, iGAIS, and MAS scores, corroborate prior ULTRAI/II findings and demonstrate the efficacy of incobotulinumtoxinA for simultaneous treatment of UFLs. Journal of cosmetic dermatology • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40968493 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of Significant improvements in PROs were demonstrated with both abrocitinib doses vs. Journal of the European Academy of Dermatology and Venereology : JEADV • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34779063 ↗ |
Flexural eczema Patient Community & “People Like Me” Threads
Filter Flexural eczema community threads and patient logs by age, biological sex, dosage, and treatment duration.